StockMacro
Menu

iBio

$0.80 -56% in 6 monthsMarket cap $56.4M

IBIO on XNAS, Health Care, iBio, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue rose 115% to $1.1M but a delisting notice arrived as cash burn reached $27.6M over 12 months.

  • BadShort interest rose 8.1% in two weeks to 5.7% of shares

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

Industry
Pharmaceutical preparations (Health Care)
Employees
23
Website
ibioinc.com
Listed
Nasdaq, US
Last results
10 Nov 2026
Next results
expected around 9 Feb 2027 (an estimate: a year ago it reported on 10 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.1M, net loss $7.6M.
Quarter to 31 Dec 2021: revenue $168K, net income -$11.9MQuarter to 31 Dec 2021: revenue $168K, net income -$11.9MQuarter to 31 Mar 2022: revenue $1.9M, net income -$12.4MQuarter to 31 Mar 2022: revenue $1.9M, net income -$12.4MQuarter to 30 Jun 2022: revenue $61K, net income -$17.1MQuarter to 30 Jun 2022: revenue $61K, net income -$17.1MQuarter to 30 Sep 2022: revenue $0, net income -$18.1MQuarter to 30 Sep 2022: revenue $0, net income -$18.1MQuarter to 31 Dec 2022: revenue $0, net income -$33.6MQuarter to 31 Dec 2022: revenue $0, net income -$33.6MQuarter to 31 Mar 2023: revenue $0, net income -$7.3MQuarter to 31 Mar 2023: revenue $0, net income -$7.3MQuarter to 30 Jun 2023: revenue –, net income -$6.0MQuarter to 30 Sep 2023: revenue $50K, net income -$5.7MQuarter to 30 Sep 2023: revenue $50K, net income -$5.7MQuarter to 31 Dec 2023: revenue –, net income -$8.2MQuarter to 31 Mar 2024: revenue –, net income -$3.2MQuarter to 30 Jun 2024: revenue $175K, net income -$7.8MQuarter to 30 Jun 2024: revenue $175K, net income -$7.8MQuarter to 30 Sep 2024: revenue $0, net income -$4.0MQuarter to 30 Sep 2024: revenue $0, net income -$4.0MQuarter to 31 Dec 2024: revenue $200K, net income -$4.4MQuarter to 31 Dec 2024: revenue $200K, net income -$4.4MQuarter to 31 Mar 2025: revenue $0, net income -$4.9MQuarter to 31 Mar 2025: revenue $0, net income -$4.9MQuarter to 30 Jun 2025: revenue $200K, net income -$5.2MQuarter to 30 Jun 2025: revenue $200K, net income -$5.2MQuarter to 30 Sep 2025: revenue $100K, net income -$5.7MQuarter to 30 Sep 2025: revenue $100K, net income -$5.7MQuarter to 31 Dec 2025: revenue $0, net income -$9.0MQuarter to 31 Dec 2025: revenue $0, net income -$9.0MQuarter to 31 Mar 2026: revenue $0, net income -$7.7MQuarter to 31 Mar 2026: revenue $0, net income -$7.7MQuarter to 30 Jun 2026: revenue $0, net income -$10.6MQuarter to 30 Jun 2026: revenue $0, net income -$10.6MQuarter to 30 Sep 2026: revenue $1.1M, net income -$7.6MQuarter to 30 Sep 2026: revenue $1.1M, net income -$7.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $33.6M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$1.1M-$7.6M
30 Jun 2026$0-$10.6M
31 Mar 2026$0-$7.7M
31 Dec 2025$0-$9.0M
30 Sep 2025$100K-$5.7M
30 Jun 2025$200K-$5.2M
31 Mar 2025$0-$4.9M
31 Dec 2024$200K-$4.4M
30 Sep 2024$0-$4.0M
30 Jun 2024$175K-$7.8M
31 Mar 2024–-$3.2M
31 Dec 2023–-$8.2M
30 Sep 2023$50K-$5.7M
30 Jun 2023–-$6.0M
31 Mar 2023$0-$7.3M
31 Dec 2022$0-$33.6M
30 Sep 2022$0-$18.1M
30 Jun 2022$61K-$17.1M
31 Mar 2022$1.9M-$12.4M
31 Dec 2021$168K-$11.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.1M $500K
Revenue growthRevenue of the last 12 months compared with the 12 months before. +115% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$34.9M -$20.1M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -51.8% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$27.6M -$17.3M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $76.7M $49.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $706K
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – -$48.9M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.12
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 52.4 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.72 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
iBioIBIO (this company) $56.4Mloss52.4+115%–
Tenax TherapeuticsTENX $56.9Mloss–––
Azora TherapeuticsAZR $55.0Mloss–––
Boundless BioBOLD $54.8Mloss–––
Rani TherapeuticsRANI $59.0Mloss9.0+449%-493%
Xilio TherapeuticsXLO $53.4Mloss0.97+73%-20.9%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+5.4%

59 13F filers vs 56

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

53%

37.5M shares held by 13F filers (30 Sep 2026) of 70.5M outstanding (10 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

5.7%

4.0M shares sold short (30 Oct 2026) of 70.5M outstanding (10 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.2

4.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+8.1%

3.7M shares sold short in the report before, 4.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

7.4%

7.4% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 41%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

2

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

11 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Price $0.80 on 20 Nov 2026, -20% over 12 months (12-month range $0.71 to $3.07)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $98K in the last 12 months (the 12 months before: $655K).
Revenue per quarter. Revenue $1.1M in the latest quarter, +975% on a year earlier.
Capital spending per quarter. Capital spending $102K in the latest quarter, +219% on a year earlier.
Institutional holders (13F filers). 59 13F filers reported holding it in the latest 13F quarter, +84% on a year earlier.
Lobbying spend. Lobbying spend: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
20 Nov 20268-K and other filingsNasdaq notice: bid price below $1.00 for 30 consecutive business days; has until May 18, 2027 to regain compliance
19 Oct 20268-K and other filingsDirector or officer change
4 Aug 20268-K and other filingsDirector or officer change
8 May 20268-K and other filingsDirector or officer change
8 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Mar 2026Sharp changeShort interest spike: short interest spike, 4.2M vs usual 1.0M (2026-02-13); 9.2x the same period a year earlier
27 Feb 20268-K and other filingsA major agreement ended
17 Feb 2026Sharp changeShort interest spike: short interest spike, 3.9M vs usual 915K (2026-01-30); 18.0x the same period a year earlier
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 25 vs usual 5.50 (2025-12-31)
3 Feb 2026Sharp changeShort interest spike: short interest spike, 3.9M vs usual 903K (2026-01-15); 16.1x the same period a year earlier
22 Jan 20268-K and other filingsPrivate placement of securities (Form D)
13 Jan 2026Sharp changeShort interest spike: short interest spike, 3.8M vs usual 877K (2025-12-31); 20.0x the same period a year earlier
30 Dec 2025Sharp changeShort interest spike: short interest spike, 3.9M vs usual 839K (2025-12-15); 15.3x the same period a year earlier
18 Nov 2025Sharp changeShort interest spike: short interest spike, 2.5M vs usual 594K (2025-10-31); 9.5x the same period a year earlier
16 Sep 2025Sharp changeShort interest spike: short interest spike, 2.1M vs usual 461K (2025-08-29); 23.8x the same period a year earlier
1 Aug 20258-K and other filingsDelisting notice or listing transfer
13 May 2025Sharp changeShort interest spike: short interest spike, 1.7M vs usual 196K (2025-04-30); 12.8x the same period a year earlier
7 May 20258-K and other filingsPrivate placement of securities (Form D)
29 Apr 2025Sharp changeShort interest spike: short interest spike, 926K vs usual 187K (2025-04-15); 5.0x the same period a year earlier
15 Apr 2025Sharp changeShort interest spike: short interest spike, 1.2M vs usual 173K (2025-03-31); 7.2x the same period a year earlier
1 Apr 2025Sharp changeShort interest spike: short interest spike, 851K vs usual 150K (2025-03-14); 14.3x the same period a year earlier
18 Mar 2025Sharp changeShort interest spike: short interest spike, 902K vs usual 136K (2025-02-28); 8.4x the same period a year earlier
19 Feb 20258-K and other filingsDelisting notice or listing transfer
14 Jan 2025Sharp changeClustered insider buying: clustered insider buying (7 independent filers, 7 filing(s) in 30 days, value_usd total 655K)
26 Jul 20248-K and other filingsDirector or officer change
9 Jul 20248-K and other filingsDirector or officer change
9 Jul 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Jun 20248-K and other filingsA major agreement ended
5 Jun 20248-K and other filingsCompleted an acquisition or asset sale
4 Apr 20248-K and other filingsPrivate placement of securities (Form D)
26 Feb 20248-K and other filingsCompleted an acquisition or asset sale
21 Feb 20248-K and other filingsChanged its auditor
30 Nov 20238-K and other filingsRegistered new securities for sale (S-1)
28 Nov 20238-K and other filingsDirector or officer change
28 Nov 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Oct 20238-K and other filingsRegistered new securities for sale (S-1)
15 Aug 20238-K and other filingsPrivate placement of securities (Form D)
4 Aug 20238-K and other filingsRegistered new securities for sale (S-1)
27 Jun 20238-K and other filingsDirector or officer change
27 Jun 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Feb 20238-K and other filingsCompleted an acquisition or asset sale
16 Feb 20238-K and other filingsRestructuring costs announced
25 Jan 20238-K and other filingsDirector or officer change
17 Jan 20238-K and other filingsDirector or officer change
2 Dec 20228-K and other filingsDirector or officer change
3 Nov 20228-K and other filingsRestructuring costs announced
3 Nov 20228-K and other filingsDirector or officer change
3 Nov 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Sep 2022Lobbying filinglobbying engagement terminated (THE PETRIZZO GROUP, INC.)
29 Sep 20228-K and other filingsReport will be filed late
21 Sep 20228-K and other filingsCompleted an acquisition or asset sale
21 Sep 20228-K and other filingsA major agreement ended
2 May 20228-K and other filingsDirector or officer change
2 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Mar 2022: -$34K published
Month from 1 Feb 2023: -$7K published
Month from 1 Mar 2023: -$11K published
Month from 1 Apr 2023: -$5K published
Month from 1 May 2023: -$4K published
Month from 1 Jun 2023: -$3K published
Month from 1 Jul 2023: -$30K published
Month from 1 Aug 2023: -$2K published
Month from 1 Oct 2023: -$3K published
Month from 1 Nov 2023: -$1K published
Month from 1 Jan 2025: $655K published
Month from 1 Mar 2026: $98K published
Revenue per quarter
Quarter ended 31 Dec 2021: $168K, -76% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $1.9M, +154% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $61K, -88% on a year earlier; public on 12 Oct 2022
Quarter ended 30 Sep 2022: $0, -100% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $0, -100% on a year earlier; public on 15 Feb 2023
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 16 May 2023
Quarter ended 30 Sep 2023: $50K; public on 15 Nov 2023
Quarter ended 30 Jun 2024: $175K; public on 21 Sep 2024
Quarter ended 30 Sep 2024: $0, -100% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $200K; public on 11 Feb 2025
Quarter ended 31 Mar 2025: $0; public on 3 May 2025
Quarter ended 30 Jun 2025: $200K, +14% on a year earlier; public on 6 Sep 2025
Quarter ended 30 Sep 2025: $100K; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $0, -100% on a year earlier; public on 11 Feb 2026
Quarter ended 31 Mar 2026: $0; public on 13 May 2026
Quarter ended 30 Jun 2026: $0, -100% on a year earlier; public on 29 Aug 2026
Quarter ended 30 Sep 2026: $1.1M, +975% on a year earlier; public on 11 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $2.1M, +115% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $644K, -35% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $3.4M, +36% on a year earlier; public on 12 Oct 2022
Quarter ended 30 Sep 2022: $2.5M, +121% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $3.0M, +38% on a year earlier; public on 15 Feb 2023
Quarter ended 30 Jun 2023: $506K, -85% on a year earlier; public on 28 Sep 2023
Quarter ended 31 Mar 2024: $0; public on 3 May 2025
Quarter ended 30 Jun 2024: $210K, -58% on a year earlier; public on 21 Sep 2024
Quarter ended 30 Sep 2024: $0; public on 13 Nov 2025
Quarter ended 31 Dec 2024: $1K; public on 11 Feb 2025
Quarter ended 30 Jun 2025: $1K, -100% on a year earlier; public on 6 Sep 2025
Quarter ended 30 Sep 2025: $32K; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $516K, +51500% on a year earlier; public on 11 Feb 2026
Quarter ended 31 Mar 2026: $11K; public on 13 May 2026
Quarter ended 30 Jun 2026: $19K, +1800% on a year earlier; public on 29 Aug 2026
Quarter ended 30 Sep 2026: $102K, +219% on a year earlier; public on 11 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 74; public on 14 Feb 2022
31 Mar 2022 report: 68; public on 16 May 2022
30 Jun 2022 report: 53; public on 15 Aug 2022
30 Sep 2022 report: 41; public on 14 Nov 2022
31 Dec 2022 report: 34; public on 14 Feb 2023
31 Mar 2023 report: 28; public on 15 May 2023
30 Jun 2023 report: 25; public on 14 Aug 2023
30 Sep 2023 report: 25; public on 14 Nov 2023
31 Dec 2023 report: 19; public on 14 Feb 2024
31 Mar 2024 report: 25; public on 15 May 2024
30 Jun 2024 report: 28; public on 14 Aug 2024
30 Sep 2024 report: 31; public on 14 Nov 2024
31 Dec 2024 report: 30; public on 14 Feb 2025
31 Mar 2025 report: 34; public on 15 May 2025
30 Jun 2025 report: 28; public on 14 Aug 2025
30 Sep 2025 report: 32; public on 14 Nov 2025
31 Dec 2025 report: 48; public on 17 Feb 2026
31 Mar 2026 report: 49; public on 15 May 2026
30 Jun 2026 report: 56; public on 14 Aug 2026
30 Sep 2026 report: 59; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $30K published
Quarter from 1 Apr 2022: $30K published
Quarter from 1 Jul 2022: $60K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $23K (27 Mar 2026), higher than 73% of its own history.
  • Insider net buying (open market): Insiders bought a net $98K in the last 12 months (the 12 months before: $655K).
  • Revenue per quarter: Revenue $1.1M in the latest quarter, +975% on a year earlier.
  • Capital spending per quarter: Capital spending $102K in the latest quarter, +219% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 34 insider trades

No trades in the last 90 days; the latest was filed 27 Mar 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
27 Mar 2026Marc BanjakChief Legal OfficerBuy13,934$1.65$23KForm 4
23 Mar 2026Martin BrennerSee RemarksBuy12,336$2.02$25KForm 4
23 Mar 2026Felipe DuranChief Financial OfficerBuy24,835$2.02$50KForm 4
13 Jan 2025David ArkowitzDirectorBuy18,382$2.72$50KForm 4
13 Jan 2025Martin BrennerSee RemarksBuy9,191$2.72$25KForm 4
13 Jan 2025Felipe DuranChief Financial OfficerBuy9,191$2.72$25KForm 4
13 Jan 2025Gary SenderDirectorBuy9,191$2.72$25KForm 4
13 Jan 2025Antonio Bernardino Guimaraes ParadaDirectorBuy183,823$2.72$500KForm 4

59 institutions reported shares at the end of Q3 2026, 53% of the shares outstanding; 11 opened a position, 5 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Silverarc Capital Management, LLC5.4M7.60%$6.3M+1.8M+52%
Affinity Asset Advisors, LLC4.1M5.86%$4.9M+123K+3.1%
Cormorant Asset Management, LP3.6M5.07%$4.2MNo change
Vestal Point Capital, LP2.6M3.69%$3.1MNo change
Woodline Partners LP2.2M3.18%$2.6M+462K+26%
Vanguard Capital Management LLC2.1M2.98%$2.5MNo change
Frazier Life Sciences Management, L.P.2.0M2.77%$2.3MNo change
Balyasny Asset Management L.P.1.6M2.26%$1.9M+421K+36%
Ensign Peak Advisors, Inc1.6M2.22%$1.8M-267K-15%
Bank of America Corp1.5M2.11%$1.8M+367K+33%

In 12 months: 3 director or officer changes, 2 major agreements, 1 private placement, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
20 Nov 2026Nasdaq notice: bid price below $1.00 for 30 consecutive business days; has until May 18, 2027 to regain compliance8-K
19 Oct 2026Director or officer changeSame filing: changed its bylaws or fiscal year, shareholder vote results8-K
4 Aug 2026Director or officer change8-K
8 May 2026Director or officer change8-K
27 Feb 2026Signed a major agreement; A major agreement ended8-K
22 Jan 2026Private placement of securities (Form D)$26.0M sold of $26.0M offeredD
12 Jan 2026Signed a major agreementSame filing: sold shares privately8-K
21 Aug 2025Signed a major agreement8-K

Reported lobbying spend: $30K in Q3 2022, $30K in Q2 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Sep 2022EndedThe Petrizzo Group, Inc.for Ibio, Inc.Advance iBio as the leader in plant-made pharmaceutical manufacturing and collaboration between the U.S. Government for research and development of domestic advanced vaccine manufacturing platforms. COVID-19 pandemic preparedness.; Funding for advanced manufacturing technologies that utilize plantsHealth issues, MED, BudgetFiling
17 May 2021EndedSteptoe LLPfor Ibio, Inc.Not statedFiling
4 Jan 2021NewThe Petrizzo Group, Inc.for Ibio, Inc.Specific focus on plant-made pharmaceutical manufacturing of vaccines, and therapies, and funding for research and direct manufacturing with the U.S. Government or other commercial partners.Health issues, MEDFiling
8 Apr 2020NewSteptoe LLPfor Ibio, Inc.Obtain funding for COVID 19 vaccine and funding to upgrade an existing production facility.Defense, Health issuesFiling
Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Feb 2026confirmed

Confirmed across sources Institutional holdings and Short interest and volume

iBio (IBIO): had 3.9M shares sold short in the 15 Jan 2026 report, 16× the same report last year, while it saw 25 13F filers open a new position in the quarter ended 31 Dec 2025, against none in the same quarter last year. Two unrelated kinds of activity within 28 days.

  • Short interest and volume: Short interest spike, became public on 28 Jan 2026
  • Institutional holdings: Many funds opening a new position, became public on 17 Feb 2026
  • Short interest and volume: Short interest spike, became public on 11 Feb 2026
  • Short interest and volume: Short interest spike, became public on 26 Feb 2026
2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M2025-11-14: 1.2M2025-11-28: 1.9M2025-12-15: 3.9M2025-12-31: 3.8M2026-01-15: 3.9M
The 15 Jan 2026 report against the 24 reports before it. this reportearliernormal: 903K
See the evidence (4 changes)

Short interest and volume: Short interest spike became public on 28 Jan 2026

iBio had 3.9M shares sold short in the 15 Jan 2026 report, 16× the same report last year.

This period
3.9M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
903K
Typical spread (median absolute deviation)
433K
How far from its usual level
+4.7
Same report last year
242K
History used
2,939 days
2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M2025-11-14: 1.2M2025-11-28: 1.9M2025-12-15: 3.9M2025-12-31: 3.8M2026-01-15: 3.9M
the 15 Jan 2026 report24 earlier reportsnormal: 903K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 17 Feb 2026

iBio saw 25 13F filers open a new position in the quarter ended 31 Dec 2025, against none in the same quarter last year.

This period
25 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
5.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+6.5
Same quarter last year
0
History used
4,475 days
2023-12-31: 32024-03-31: 82024-06-30: 72024-09-30: 42024-12-31: 02025-03-31: 72025-06-30: 62025-09-30: 52025-12-31: 25
the quarter ended 31 Dec 20258 earlier quartersnormal: 5.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 11 Feb 2026

iBio had 3.9M shares sold short in the 30 Jan 2026 report, 18× the same report last year.

This period
3.9M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
915K
Typical spread (median absolute deviation)
444K
How far from its usual level
+4.5
Same report last year
214K
History used
2,954 days
2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M2025-11-14: 1.2M2025-11-28: 1.9M2025-12-15: 3.9M2025-12-31: 3.8M2026-01-15: 3.9M2026-01-30: 3.9M
the 30 Jan 2026 report24 earlier reportsnormal: 915K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Feb 2026

iBio had 4.2M shares sold short in the 13 Feb 2026 report, 9.2× the same report last year.

This period
4.2M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
1.0M
Typical spread (median absolute deviation)
557K
How far from its usual level
+3.8
Same report last year
454K
History used
2,968 days
2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M2025-11-14: 1.2M2025-11-28: 1.9M2025-12-15: 3.9M2025-12-31: 3.8M2026-01-15: 3.9M2026-01-30: 3.9M2026-02-13: 4.2M
the 13 Feb 2026 report24 earlier reportsnormal: 1.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

19 May 2020confirmed

Confirmed across sources Lobbying and Short interest and volume

iBio (IBIO): had 4.0M shares sold short in the 30 Apr 2020 report, 11× the same report last year, while it registered for federal lobbying for the first time in our data (Steptoe Llp). Two unrelated kinds of activity within 35 days.

  • Short interest and volume: Short interest spike, became public on 25 Apr 2020
  • Short interest and volume: Short interest spike, became public on 12 May 2020
  • Lobbying: First lobbying registration, became public on 19 May 2020
  • Short interest and volume: Short interest spike, became public on 28 May 2020
2019-04-30: 361K2019-05-15: 303K2019-05-31: 245K2019-06-14: 232K2019-06-28: 173K2019-07-15: 161K2019-07-31: 91K2019-08-15: 78K2019-08-30: 148K2019-09-13: 213K2019-09-30: 1.0M2019-10-15: 1.1M2019-10-31: 59K2019-11-15: 53K2019-11-29: 324K2019-12-13: 1.8M2019-12-31: 361K2020-01-15: 521K2020-01-31: 3.6M2020-02-14: 8.0M2020-02-28: 4.6M2020-03-13: 7.4M2020-03-31: 2.9M2020-04-15: 2.5M2020-04-30: 4.0M
The 30 Apr 2020 report against the 24 reports before it. this reportearliernormal: 342K
See the evidence (4 changes)

Short interest and volume: Short interest spike became public on 25 Apr 2020

iBio had 2.5M shares sold short in the 15 Apr 2020 report, 6.8× the same report last year.

This period
2.5M (the 15 Apr 2020 report)
Normal report (median of 24 earlier)
342K
Typical spread (median absolute deviation)
223K
How far from its usual level
+6.5
Same report last year
365K
History used
838 days
2019-04-15: 365K2019-04-30: 361K2019-05-15: 303K2019-05-31: 245K2019-06-14: 232K2019-06-28: 173K2019-07-15: 161K2019-07-31: 91K2019-08-15: 78K2019-08-30: 148K2019-09-13: 213K2019-09-30: 1.0M2019-10-15: 1.1M2019-10-31: 59K2019-11-15: 53K2019-11-29: 324K2019-12-13: 1.8M2019-12-31: 361K2020-01-15: 521K2020-01-31: 3.6M2020-02-14: 8.0M2020-02-28: 4.6M2020-03-13: 7.4M2020-03-31: 2.9M2020-04-15: 2.5M
the 15 Apr 2020 report24 earlier reportsnormal: 342K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 May 2020

iBio had 4.0M shares sold short in the 30 Apr 2020 report, 11× the same report last year.

This period
4.0M (the 30 Apr 2020 report)
Normal report (median of 24 earlier)
342K
Typical spread (median absolute deviation)
257K
How far from its usual level
+9.6
Same report last year
361K
History used
853 days
2019-04-30: 361K2019-05-15: 303K2019-05-31: 245K2019-06-14: 232K2019-06-28: 173K2019-07-15: 161K2019-07-31: 91K2019-08-15: 78K2019-08-30: 148K2019-09-13: 213K2019-09-30: 1.0M2019-10-15: 1.1M2019-10-31: 59K2019-11-15: 53K2019-11-29: 324K2019-12-13: 1.8M2019-12-31: 361K2020-01-15: 521K2020-01-31: 3.6M2020-02-14: 8.0M2020-02-28: 4.6M2020-03-13: 7.4M2020-03-31: 2.9M2020-04-15: 2.5M2020-04-30: 4.0M
the 30 Apr 2020 report24 earlier reportsnormal: 342K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Lobbying: First lobbying registration became public on 19 May 2020

iBio registered for federal lobbying for the first time in our data (Steptoe Llp).

Source coverage starts
5 Oct 2010
Earlier events of other kinds
0

"First" means first in our data: it fires only when the source's history began at least 365 days earlier.

Short interest and volume: Short interest spike became public on 28 May 2020

iBio had 2.8M shares sold short in the 15 May 2020 report, 9.4× the same report last year.

This period
2.8M (the 15 May 2020 report)
Normal report (median of 24 earlier)
343K
Typical spread (median absolute deviation)
274K
How far from its usual level
+6.1
Same report last year
303K
History used
868 days
2019-05-15: 303K2019-05-31: 245K2019-06-14: 232K2019-06-28: 173K2019-07-15: 161K2019-07-31: 91K2019-08-15: 78K2019-08-30: 148K2019-09-13: 213K2019-09-30: 1.0M2019-10-15: 1.1M2019-10-31: 59K2019-11-15: 53K2019-11-29: 324K2019-12-13: 1.8M2019-12-31: 361K2020-01-15: 521K2020-01-31: 3.6M2020-02-14: 8.0M2020-02-28: 4.6M2020-03-13: 7.4M2020-03-31: 2.9M2020-04-15: 2.5M2020-04-30: 4.0M2020-05-15: 2.8M
the 15 May 2020 report24 earlier reportsnormal: 343K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 20 Nov 2026Filings record

    Nasdaq notice: bid price below $1.00 for 30 consecutive business days; has until May 18, 2027 to regain compliance

  2. 19 Oct 2026Filings record

    Director or officer change

  3. 4 Aug 2026Filings record

    Director or officer change

  4. 8 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 8 May 2026Filings record

    Director or officer change

  6. 28 Mar 2026Insiders record

    Banjak Marc (Chief Legal Officer) bought 13,934 shares of IBIO ($23,024) (dated 27 Mar 2026)

  7. 24 Mar 2026Insiders record

    Brenner Martin (See Remarks) bought 12,336 shares of IBIO ($24,919) (dated 23 Mar 2026)

  8. 24 Mar 2026Insiders record

    Duran Felipe (Chief Financial Officer) bought 24,835 shares of IBIO ($50,167) (dated 23 Mar 2026)

  9. 27 Feb 2026Filings record

    A major agreement ended

  10. 26 Feb 2026Short interest and volume change

    had 4.2M shares sold short in the 13 Feb 2026 report, 9.2× the same report last year.

    Same report last year: 454K; its normal report is 1.0M.

    See the evidence
    This period
    4.2M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    1.0M
    Typical spread (median absolute deviation)
    557K
    How far from its usual level
    +3.8
    Same report last year
    454K
    History used
    2,968 days
    2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M2025-11-14: 1.2M2025-11-28: 1.9M2025-12-15: 3.9M2025-12-31: 3.8M2026-01-15: 3.9M2026-01-30: 3.9M2026-02-13: 4.2M
    the 13 Feb 2026 report24 earlier reportsnormal: 1.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 17 Feb 2026several at once

    had 3.9M shares sold short in the 15 Jan 2026 report, 16× the same report last year, while it saw 25 13F filers open a new position in the quarter ended 31 Dec 2025, against none in the same quarter last year. Two unrelated kinds of activity within 28 days.

    See the evidence (4 changes)

    Short interest and volume: Short interest spike became public on 28 Jan 2026

    iBio had 3.9M shares sold short in the 15 Jan 2026 report, 16× the same report last year.

    This period
    3.9M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    903K
    Typical spread (median absolute deviation)
    433K
    How far from its usual level
    +4.7
    Same report last year
    242K
    History used
    2,939 days
    2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M2025-11-14: 1.2M2025-11-28: 1.9M2025-12-15: 3.9M2025-12-31: 3.8M2026-01-15: 3.9M
    the 15 Jan 2026 report24 earlier reportsnormal: 903K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 17 Feb 2026

    iBio saw 25 13F filers open a new position in the quarter ended 31 Dec 2025, against none in the same quarter last year.

    This period
    25 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    5.5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +6.5
    Same quarter last year
    0
    History used
    4,475 days
    2023-12-31: 32024-03-31: 82024-06-30: 72024-09-30: 42024-12-31: 02025-03-31: 72025-06-30: 62025-09-30: 52025-12-31: 25
    the quarter ended 31 Dec 20258 earlier quartersnormal: 5.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 11 Feb 2026

    iBio had 3.9M shares sold short in the 30 Jan 2026 report, 18× the same report last year.

    This period
    3.9M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    915K
    Typical spread (median absolute deviation)
    444K
    How far from its usual level
    +4.5
    Same report last year
    214K
    History used
    2,954 days
    2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M2025-11-14: 1.2M2025-11-28: 1.9M2025-12-15: 3.9M2025-12-31: 3.8M2026-01-15: 3.9M2026-01-30: 3.9M
    the 30 Jan 2026 report24 earlier reportsnormal: 915K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Feb 2026

    iBio had 4.2M shares sold short in the 13 Feb 2026 report, 9.2× the same report last year.

    This period
    4.2M (the 13 Feb 2026 report)
    Normal report (median of 24 earlier)
    1.0M
    Typical spread (median absolute deviation)
    557K
    How far from its usual level
    +3.8
    Same report last year
    454K
    History used
    2,968 days
    2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M2025-11-14: 1.2M2025-11-28: 1.9M2025-12-15: 3.9M2025-12-31: 3.8M2026-01-15: 3.9M2026-01-30: 3.9M2026-02-13: 4.2M
    the 13 Feb 2026 report24 earlier reportsnormal: 1.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  12. 17 Feb 2026Institutional holdings change

    saw 25 13F filers open a new position in the quarter ended 31 Dec 2025, against none in the same quarter last year.

    See the evidence
    This period
    25 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    5.5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +6.5
    Same quarter last year
    0
    History used
    4,475 days
    2023-12-31: 32024-03-31: 82024-06-30: 72024-09-30: 42024-12-31: 02025-03-31: 72025-06-30: 62025-09-30: 52025-12-31: 25
    the quarter ended 31 Dec 20258 earlier quartersnormal: 5.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  13. 11 Feb 2026Short interest and volume change

    had 3.9M shares sold short in the 30 Jan 2026 report, 18× the same report last year.

    Same report last year: 214K; its normal report is 915K.

    See the evidence
    This period
    3.9M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    915K
    Typical spread (median absolute deviation)
    444K
    How far from its usual level
    +4.5
    Same report last year
    214K
    History used
    2,954 days
    2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M2025-11-14: 1.2M2025-11-28: 1.9M2025-12-15: 3.9M2025-12-31: 3.8M2026-01-15: 3.9M2026-01-30: 3.9M
    the 30 Jan 2026 report24 earlier reportsnormal: 915K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 28 Jan 2026Short interest and volume change

    had 3.9M shares sold short in the 15 Jan 2026 report, 16× the same report last year.

    Same report last year: 242K; its normal report is 903K.

    See the evidence
    This period
    3.9M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    903K
    Typical spread (median absolute deviation)
    433K
    How far from its usual level
    +4.7
    Same report last year
    242K
    History used
    2,939 days
    2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M2025-11-14: 1.2M2025-11-28: 1.9M2025-12-15: 3.9M2025-12-31: 3.8M2026-01-15: 3.9M
    the 15 Jan 2026 report24 earlier reportsnormal: 903K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 22 Jan 2026Filings record

    Private placement of securities (Form D)

  16. 13 Jan 2026Short interest and volume change

    had 3.8M shares sold short in the 31 Dec 2025 report, 20× the same report last year.

    Same report last year: 190K; its normal report is 877K.

    See the evidence
    This period
    3.8M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    877K
    Typical spread (median absolute deviation)
    406K
    How far from its usual level
    +4.8
    Same report last year
    190K
    History used
    2,924 days
    2024-12-31: 190K2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M2025-11-14: 1.2M2025-11-28: 1.9M2025-12-15: 3.9M2025-12-31: 3.8M
    the 31 Dec 2025 report24 earlier reportsnormal: 877K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 25 Dec 2025Short interest and volume change

    had 3.9M shares sold short in the 15 Dec 2025 report, 15× the same report last year.

    Same report last year: 256K; its normal report is 839K.

    See the evidence
    This period
    3.9M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    839K
    Typical spread (median absolute deviation)
    369K
    How far from its usual level
    +5.6
    Same report last year
    256K
    History used
    2,908 days
    2024-12-13: 256K2024-12-31: 190K2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M2025-11-14: 1.2M2025-11-28: 1.9M2025-12-15: 3.9M
    the 15 Dec 2025 report24 earlier reportsnormal: 839K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 13 Nov 2025Short interest and volume change

    had 2.5M shares sold short in the 31 Oct 2025 report, 9.5× the same report last year.

    Same report last year: 260K; its normal report is 594K.

    See the evidence
    This period
    2.5M (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    594K
    Typical spread (median absolute deviation)
    333K
    How far from its usual level
    +3.8
    Same report last year
    260K
    History used
    2,863 days
    2024-10-31: 260K2024-11-15: 231K2024-11-29: 203K2024-12-13: 256K2024-12-31: 190K2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M2025-09-15: 904K2025-09-30: 473K2025-10-15: 412K2025-10-31: 2.5M
    the 31 Oct 2025 report24 earlier reportsnormal: 594K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 11 Sep 2025Short interest and volume change

    had 2.1M shares sold short in the 29 Aug 2025 report, 24× the same report last year.

    Same report last year: 90K; its normal report is 461K.

    See the evidence
    This period
    2.1M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    461K
    Typical spread (median absolute deviation)
    265K
    How far from its usual level
    +4.3
    Same report last year
    90K
    History used
    2,800 days
    2024-08-30: 90K2024-09-13: 86K2024-09-30: 138K2024-10-15: 308K2024-10-31: 260K2024-11-15: 231K2024-11-29: 203K2024-12-13: 256K2024-12-31: 190K2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M2025-05-15: 657K2025-05-30: 634K2025-06-13: 828K2025-06-30: 2.3M2025-07-15: 468K2025-07-31: 554K2025-08-15: 1.1M2025-08-29: 2.1M
    the 29 Aug 2025 report24 earlier reportsnormal: 461K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 1 Aug 2025Filings record

    Delisting notice or listing transfer

  21. 10 May 2025Short interest and volume change

    had 1.7M shares sold short in the 30 Apr 2025 report, 13× the same report last year.

    Same report last year: 135K; its normal report is 196K.

    See the evidence
    This period
    1.7M (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    196K
    Typical spread (median absolute deviation)
    103K
    How far from its usual level
    +10.0
    Same report last year
    135K
    History used
    2,679 days
    2024-04-30: 135K2024-05-15: 81K2024-05-31: 95K2024-06-14: 134K2024-06-28: 91K2024-07-15: 101K2024-07-31: 76K2024-08-15: 79K2024-08-30: 90K2024-09-13: 86K2024-09-30: 138K2024-10-15: 308K2024-10-31: 260K2024-11-15: 231K2024-11-29: 203K2024-12-13: 256K2024-12-31: 190K2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K2025-04-30: 1.7M
    the 30 Apr 2025 report24 earlier reportsnormal: 196K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 7 May 2025Filings record

    Private placement of securities (Form D)

  23. 26 Apr 2025Short interest and volume change

    had 926K shares sold short in the 15 Apr 2025 report, 5.0× the same report last year.

    Same report last year: 184K; its normal report is 187K.

    See the evidence
    This period
    926K (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    187K
    Typical spread (median absolute deviation)
    89K
    How far from its usual level
    +5.6
    Same report last year
    184K
    History used
    2,664 days
    2024-04-15: 184K2024-04-30: 135K2024-05-15: 81K2024-05-31: 95K2024-06-14: 134K2024-06-28: 91K2024-07-15: 101K2024-07-31: 76K2024-08-15: 79K2024-08-30: 90K2024-09-13: 86K2024-09-30: 138K2024-10-15: 308K2024-10-31: 260K2024-11-15: 231K2024-11-29: 203K2024-12-13: 256K2024-12-31: 190K2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M2025-04-15: 926K
    the 15 Apr 2025 report24 earlier reportsnormal: 187K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 10 Apr 2025Short interest and volume change

    had 1.2M shares sold short in the 31 Mar 2025 report, 7.2× the same report last year.

    Same report last year: 162K; its normal report is 173K.

    See the evidence
    This period
    1.2M (the 31 Mar 2025 report)
    Normal report (median of 24 earlier)
    173K
    Typical spread (median absolute deviation)
    80K
    How far from its usual level
    +8.4
    Same report last year
    162K
    History used
    2,649 days
    2024-03-28: 162K2024-04-15: 184K2024-04-30: 135K2024-05-15: 81K2024-05-31: 95K2024-06-14: 134K2024-06-28: 91K2024-07-15: 101K2024-07-31: 76K2024-08-15: 79K2024-08-30: 90K2024-09-13: 86K2024-09-30: 138K2024-10-15: 308K2024-10-31: 260K2024-11-15: 231K2024-11-29: 203K2024-12-13: 256K2024-12-31: 190K2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K2025-03-31: 1.2M
    the 31 Mar 2025 report24 earlier reportsnormal: 173K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 26 Mar 2025Short interest and volume change

    had 851K shares sold short in the 14 Mar 2025 report, 14× the same report last year.

    Same report last year: 59K; its normal report is 150K.

    See the evidence
    This period
    851K (the 14 Mar 2025 report)
    Normal report (median of 24 earlier)
    150K
    Typical spread (median absolute deviation)
    64K
    How far from its usual level
    +7.4
    Same report last year
    59K
    History used
    2,632 days
    2024-03-15: 59K2024-03-28: 162K2024-04-15: 184K2024-04-30: 135K2024-05-15: 81K2024-05-31: 95K2024-06-14: 134K2024-06-28: 91K2024-07-15: 101K2024-07-31: 76K2024-08-15: 79K2024-08-30: 90K2024-09-13: 86K2024-09-30: 138K2024-10-15: 308K2024-10-31: 260K2024-11-15: 231K2024-11-29: 203K2024-12-13: 256K2024-12-31: 190K2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K2025-03-14: 851K
    the 14 Mar 2025 report24 earlier reportsnormal: 150K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 12 Mar 2025Short interest and volume change

    had 902K shares sold short in the 28 Feb 2025 report, 8.4× the same report last year.

    Same report last year: 107K; its normal report is 136K.

    See the evidence
    This period
    902K (the 28 Feb 2025 report)
    Normal report (median of 24 earlier)
    136K
    Typical spread (median absolute deviation)
    55K
    How far from its usual level
    +9.5
    Same report last year
    107K
    History used
    2,618 days
    2024-02-29: 107K2024-03-15: 59K2024-03-28: 162K2024-04-15: 184K2024-04-30: 135K2024-05-15: 81K2024-05-31: 95K2024-06-14: 134K2024-06-28: 91K2024-07-15: 101K2024-07-31: 76K2024-08-15: 79K2024-08-30: 90K2024-09-13: 86K2024-09-30: 138K2024-10-15: 308K2024-10-31: 260K2024-11-15: 231K2024-11-29: 203K2024-12-13: 256K2024-12-31: 190K2025-01-15: 242K2025-01-31: 214K2025-02-14: 454K2025-02-28: 902K
    the 28 Feb 2025 report24 earlier reportsnormal: 136K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 19 Feb 2025Filings record

    Delisting notice or listing transfer

  28. 14 Jan 2025Insiders change

    had 7 insiders buy $655K of its shares on the open market within 30 days (7 filings).

    Who bought: Arkowitz David, Brenner Martin, Duran Felipe, Sender Gary and 3 more.

    See the evidence (7 source records)
    Independent buyers
    7
    Purchase filings (Form 4, code P)
    7
    Total bought
    $655K
    Window
    15 Dec 2024 to 14 Jan 2025
    • Arkowitz David (director) bought 18,382 shares of IBIO ($49,999)dated 13 Jan 2025, public 14 Jan 2025
    • Brenner Martin (See Remarks) bought 9,191 shares of IBIO ($25,000)dated 13 Jan 2025, public 14 Jan 2025
    • Duran Felipe (Chief Financial Officer) bought 9,191 shares of IBIO ($25,000)dated 13 Jan 2025, public 14 Jan 2025
    • Sender Gary (director) bought 9,191 shares of IBIO ($25,000)dated 13 Jan 2025, public 14 Jan 2025
    • Parada Antonio Bernardino Guimaraes (director) bought 183,823 shares of IBIO ($499,999)dated 13 Jan 2025, public 14 Jan 2025
    • Banjak Marc (Chief Legal Officer) bought 9,191 shares of IBIO ($25,000)dated 13 Jan 2025, public 14 Jan 2025
    • Clark William D (director) bought 1,838 shares of IBIO ($4,999)dated 13 Jan 2025, public 14 Jan 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  29. 14 Jan 2025Insiders record

    Arkowitz David (director) bought 18,382 shares of IBIO ($49,999) (dated 13 Jan 2025)

  30. 14 Jan 2025Insiders record

    Brenner Martin (See Remarks) bought 9,191 shares of IBIO ($25,000) (dated 13 Jan 2025)

  31. 14 Jan 2025Insiders record

    Duran Felipe (Chief Financial Officer) bought 9,191 shares of IBIO ($25,000) (dated 13 Jan 2025)

  32. 14 Jan 2025Insiders record

    Sender Gary (director) bought 9,191 shares of IBIO ($25,000) (dated 13 Jan 2025)

  33. 14 Jan 2025Insiders record

    Parada Antonio Bernardino Guimaraes (director) bought 183,823 shares of IBIO ($499,999) (dated 13 Jan 2025)

  34. 14 Jan 2025Insiders record

    Banjak Marc (Chief Legal Officer) bought 9,191 shares of IBIO ($25,000) (dated 13 Jan 2025)

  35. 14 Jan 2025Insiders record

    Clark William D (director) bought 1,838 shares of IBIO ($4,999) (dated 13 Jan 2025)

  36. 26 Jul 2024Filings record

    Director or officer change

  37. 9 Jul 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 9 Jul 2024Filings record

    Director or officer change

  39. 5 Jun 2024Filings record

    Completed an acquisition or asset sale

  40. 5 Jun 2024Filings record

    A major agreement ended

Showing the newest 40 of 140 entries; narrow the window or the kind of data to see older ones.

Not listed: 196 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001420720
Ticker
IBIO
Domain
ibioinc.com
Hq location
NY|NEW YORK|10022 (1 unverified)
Lobbying client
ibio
Name
iBio, Inc., iBioPharma, Inc., InB:Biotechnologies, Inc.
  • Federal lobbying disclosures (LDA)4 records, 30 data points8 Apr 2020 to 30 Sep 2022
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)258 records14 Jan 2016 to 20 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)967 data points30 Jun 2010 to 10 Nov 2026
  • SEC Form 4 insider transactions34 records, 104 data points27 Jan 2016 to 27 Mar 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026